Utility of serum free light chain analysis when screening for lymphoproliferative disorders: The experience at a district general hospital in the United Kingdom

Laboratory Medicine

Volumn 40, Issue 6, 2009, Pages 325-329

  Robson, Ewan J D ^a   Taylor, Joanne ^a   Beardsmore, Claire ^a   Basu, Supratik ^a   Mead, Graham ^a,b   Lovatt, Tracy ^a  

^a NEW CROSS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASSAY; CANCER SCREENING; DIAGNOSTIC VALUE; HUMAN; LIGHT CHAIN; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; REVIEW; SCREENING TEST; SERUM; UNITED KINGDOM;

EID: 77951987010     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/M6YUPSL3EIR7KE     Document Type: Review

References (25)

1. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47:673-680.
2. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132:410-451.
3. Katzmann JA, Dispenzieri A, Kyle RA, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc. 2006;81:1575-1578. (Pubitemid 44871901)
4. Wochner RD, Strober W, Waldmann TA. The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med. 1967;126:207-221.
5. Maack T, Johnson V, Kau ST, et al. Renal filtration, transport, and metabolism of low-molecular-weight proteins: A review. Kidney Int. 1979;16:251-270. (Pubitemid 10208487)
6. Hill PG, Forsyth JM, Rai B, et al. Serum free light chains: An alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem. 2006;52:1743-1748. (Pubitemid 44330709)
7. Holding S,. Spradbery D, Robson EJD, et al. Combination of serum free light chain analysis with capillary zone electrophoresis improves screening for monoclonal gammopathies. Blood. 2007;110:Abst 1497
8. Bradwell AR, Carr-Smith HD, Mead GP, et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2003;361:489-491.
9. Drayson M, Tang LX, Drew R, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97:2900-2902.
10. Mead GP, Carr-Smith H, Drayson MT, et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol. 2004;126:348-354. (Pubitemid 39005714)
11. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78-84. (Pubitemid 36819341)
12. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812-817.
13. Bakshi NA, Gulbranson R, Garstka D, et al. Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing M proteins. Am J Clin Pathol. 2005;124:214-218. (Pubitemid 41060131)
14. Abadie JM, Bankson DD. Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population. Ann Clin Lab Sci. 2006;36:157-162.
15. Piehler AP, Gulbrandsen N, Kierulf P, et al. Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population. Clin Chem. 2008;54:1823-1830.
16. Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1684-1690.
17. Katzmann JA, Clark RJ, Rajkumar VS, et al. Monoclonal light chains in sera from healthy individuals: FLC MGUS. Clin Chem. 2003;49:A-74: pA24.
18. Weiss BM, Verma P, Abadie J, et al. A pre-existing plasma cell disorder occurs in most patients with multiple myeloma. Blood. 2008;112:Abst 1693
19. Kyle RA, Greipp PR. «Idiopathic» Bence Jones proteinuria: Long-term follow-up in seven patients. New Engl J Med. 1982;306:564-567.
20. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437-1444.
21. Beetham R, Wassell J, Wallage MJ, et al. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies? Ann Clin Biochem. 2007;44:516-522.
22. Pattenden RJ, Rogers SY, Wenham PR. Serum free light chains: The need to establish local reference intervals. Ann Clin Biochem. 2007;44:512-515.
23. Kang SY, Suh JT, Lee HJ, et al. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. Ann Hematol. 2005;84:588-593.
24. Hutchison CA, Plant T, Drayson M, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrology. 2008;9:11.
25. Mead GP, Stubbs PD, Goodman HJB, et al. Comparison of serum versus urine analysis for the identification of monoclonal free light chain production in 219 patients with AL amyloidosis. Hematol Meeting Reports. 2008;2:26.